Literature DB >> 1890148

Expression of aromatase cytochrome P-450 in premenopausal and postmenopausal human ovaries: an immunocytochemical study.

S E Inkster1, A M Brodie.   

Abstract

The cellular distribution of the aromatase cytochrome P-450 enzyme in human ovaries has been investigated immunocytochemically, using an aromatase-specific monoclonal antibody. Ovaries of females ranging in age from prepubertal infant girl through to postmenopausal adulthood were obtained from immediate autopsy or after surgery. The results have revealed temporal and spatial changes in expression of aromatase at different stages of development. No immunoreactive aromatase was detected in the ovary of the 2.5 month infant. In premenopausal ovaries, aromatase was absent from the stromal compartment, but in follicles, a consistent pattern in expression of aromatase was observed, related to their size and developmental stage. Aromatase was not expressed in primordial, primary, or small secondary follicles less than 250 microns diameter. In slightly larger follicles (250-700 microns diameter) aromatase was first detected in a few thecal cells (TC). In more developed secondary through to large preovulatory follicles (greater than 1 cm) TC aromatase immunostain increased in intensity and number of positive cells, and the reaction was localized to a band of theca interna (TI) cells at the TI/theca externa interface. In granulosa cells (GC), aromatase was first detected in follicles in the initial stages of antrum formation (greater than 700 microns), and staining intensified as follicle diameter and antral cavity increased, being maximal in preovulatory follicles. GC aromatase was always found in the presence of TI immunostain. These two cell populations were separated by an unstained layer of TI cells giving the follicle walls a banded appearance. Immunostain was most intense in mural GC, was weaker in antral GC cells and was absent from the cumulus GC. Immunoreactive aromatase was also detected in functional corpora lutea (CL) but was absent from involuting CL's and corpora albicans. Our findings indicate that the immunostained cells of the CL are comprised of the former GC and possibly a subpopulation of former TI cells. In perimenopausal ovaries there was no evidence of any follicular or stromal aromatase immunostain. In postmenopausal ovaries no follicles were observed, but individual cells and clusters of cells in the stromal compartment of 3/7 specimens were found to have an aromatase immunostain reaction. In all cases, the aromatase immunostain reaction was cytoplasmic. The results provide the first direct evidence of the existence of TC aromatase, and of stromal cell aromatase in postmenopausal women.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1890148     DOI: 10.1210/jcem-73-4-717

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  8 in total

Review 1.  Functional pathology of human ovarian steroidogenesis: Normal cycling ovary and steroid-producing neoplasms.

Authors:  Hironobu Sasano
Journal:  Endocr Pathol       Date:  1994-06       Impact factor: 3.943

Review 2.  Comprehensive pharmacology and clinical efficacy of aromatase inhibitors.

Authors:  V C Njar; A M Brodie
Journal:  Drugs       Date:  1999-08       Impact factor: 9.546

Review 3.  Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer.

Authors:  V Craig Jordan; Angela M H Brodie
Journal:  Steroids       Date:  2006-12-13       Impact factor: 2.668

4.  Regulation of granulosa and theca cell transcriptomes during ovarian antral follicle development.

Authors:  Michael K Skinner; Michelle Schmidt; Marina I Savenkova; Ingrid Sadler-Riggleman; Eric E Nilsson
Journal:  Mol Reprod Dev       Date:  2008-09       Impact factor: 2.609

5.  Aromatase in human common epithelial ovarian neoplasms.

Authors:  K Kaga; H Sasano; N Harada; M Ozaki; S Sato; A Yajima
Journal:  Am J Pathol       Date:  1996-07       Impact factor: 4.307

6.  A novel phenotype related to partial loss of function mutations of the follicle stimulating hormone receptor.

Authors:  I Beau; P Touraine; G Meduri; A Gougeon; A Desroches; C Matuchansky; E Milgrom; F Kuttenn; M Misrahi
Journal:  J Clin Invest       Date:  1998-10-01       Impact factor: 14.808

Review 7.  The Coffey Lecture: steroidogenic enzyme inhibitors and hormone dependent cancer.

Authors:  Angela Brodie; Vincent Njar; Luciana Furtado Macedo; T Sean Vasaitis; Gauri Sabnis
Journal:  Urol Oncol       Date:  2009 Jan-Feb       Impact factor: 3.498

8.  Immunoexpression of aromatase cytochrome P450 and 17β-hydroxysteroid dehydrogenase in women's ovaries after menopause.

Authors:  Agnieszka Brodowska; Jacek Brodowski; Maria Laszczyńska; Sylwia Słuczanowska-Głąbowska; Bogdan Rumianowski; Iwona Rotter; Andrzej Starczewski; Mariusz Z Ratajczak
Journal:  J Ovarian Res       Date:  2014-05-10       Impact factor: 4.234

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.